This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George J. Brewer, MD
Departments of Human Genetics and Internal Medicine University of Michigan Medical School Ann Arbor, MI 48109

Vilma Yuzbasiyan-Gurkan, PhD
Department of Human Genetics University of Michigan Medical School

Arch Neurol. 1989;46(4):360-361.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We wish to respond to certain elements in the accompanying LETTERS TO THE EDITOR by Hoogenraad and Van Hattum and by Pall and coworkers concerning our recent article in the ARCHIVES.¹

Hoogenraad and Van Hattum say "it would have been better to start treatment with zinc" in the patient in the case report, and "it is difficult to understand why Brewer and coworkers waited so long to switch over to zinc therapy." We made it clear in the article that the patient had been started on penicillamine by other physicians and the patient was not referred to us until six weeks after therapy had been initiated. As we said in the article, we did not switch the patient over to zinc therapy at that point, because we believed that the patient had already been through the syndrome of neurologic worsening from penicillamine. As our data show in the ARCHIVES . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?